These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 8846227)

  • 1. The pharmacotherapy of Alzheimer's disease based on the cholinergic hypothesis: an update.
    Weinstock M
    Neurodegeneration; 1995 Dec; 4(4):349-56. PubMed ID: 8846227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer's Disease: Nexus of Cholinergic and Nerve Growth Factor Dysfunction.
    Moss DE; Perez RG
    Curr Alzheimer Res; 2021; 18(13):1010-1022. PubMed ID: 34911424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET studies and cholinergic therapy in Alzheimer's disease.
    Nordberg A
    Rev Neurol (Paris); 1999; 155 Suppl 4():S53-63. PubMed ID: 10637939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of cholinesterase inhibitors on attention.
    Pepeu G; Giovannini MG; Bracco L
    Chem Biol Interact; 2013 Mar; 203(1):361-4. PubMed ID: 23047023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholinergic therapies for Alzheimer's disease. Palliative or disease altering?
    Davis RE; Doyle PD; Carroll RT; Emmerling MR; Jaen J
    Arzneimittelforschung; 1995 Mar; 45(3A):425-31. PubMed ID: 7763338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Acetylcholinesterase inhibitors for treatment of Alzheimer's disease].
    Shinagawa S; Shigeta M
    Brain Nerve; 2014 May; 66(5):507-16. PubMed ID: 24807367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Alzheimer's disease: an evaluation of the cholinergic approach.
    Lemière J; Van Gool D; Dom R
    Acta Neurol Belg; 1999 Jun; 99(2):96-106. PubMed ID: 10427352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors.
    Sugimoto H; Yamanishi Y; Iimura Y; Kawakami Y
    Curr Med Chem; 2000 Mar; 7(3):303-39. PubMed ID: 10637367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
    Pacheco G; Palacios-Esquivel R; Moss DE
    J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies that support declining cholinergic neurotransmission in Alzheimer's disease patients.
    Sirviö J
    Gerontology; 1999; 45 Suppl 1():3-14. PubMed ID: 9876213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of cholinesterase inhibitors on learning and memory in rats: a brief review with special reference to THA.
    Mohammed AH
    Acta Neurol Scand Suppl; 1993; 149():13-5. PubMed ID: 8128832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of Alzheimer's disease].
    López OL; Becker JT
    Rev Neurol; 2002 Nov 1-15; 35(9):850-9. PubMed ID: 12436384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New classes of AChE inhibitors with additional pharmacological effects of interest for the treatment of Alzheimer's disease.
    Villarroya M; García AG; Marco JL
    Curr Pharm Des; 2004; 10(25):3177-84. PubMed ID: 15544507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholinesterases: new roles in brain function and in Alzheimer's disease.
    Giacobini E
    Neurochem Res; 2003 Apr; 28(3-4):515-22. PubMed ID: 12675140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches?
    Amenta F; Parnetti L; Gallai V; Wallin A
    Mech Ageing Dev; 2001 Nov; 122(16):2025-40. PubMed ID: 11589920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).
    McHardy SF; Wang HL; McCowen SV; Valdez MC
    Expert Opin Ther Pat; 2017 Apr; 27(4):455-476. PubMed ID: 27967267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alzheimer's disease: Targeting the Cholinergic System.
    Ferreira-Vieira TH; Guimaraes IM; Silva FR; Ribeiro FM
    Curr Neuropharmacol; 2016; 14(1):101-15. PubMed ID: 26813123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mechanisms of neurodegenerative processes and current pharmacotherapy of Alzheimer's disease.
    Gongadze N; Antelava N; Kezeli T; Okudjava M; Pachkoria K
    Georgian Med News; 2008 Feb; (155):44-8. PubMed ID: 18401056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase.
    Greig NH; Utsuki T; Yu Q; Zhu X; Holloway HW; Perry T; Lee B; Ingram DK; Lahiri DK
    Curr Med Res Opin; 2001; 17(3):159-65. PubMed ID: 11900310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics.
    Greig NH; De Micheli E; Holloway HW; Yu QS; Utsuki T; Perry TA; Brossi A; Ingram DK; Deutsch J; Lahiri DK; Soncrant TT
    Acta Neurol Scand Suppl; 2000; 176():74-84. PubMed ID: 11261809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.